Compare BBD & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBD | A |
|---|---|---|
| Founded | 1943 | 1999 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4B | 39.8B |
| IPO Year | N/A | 1999 |
| Metric | BBD | A |
|---|---|---|
| Price | $3.52 | $145.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 15 |
| Target Price | $2.55 | ★ $164.13 |
| AVG Volume (30 Days) | ★ 25.6M | 2.0M |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | ★ 4.98% | 0.70% |
| EPS Growth | ★ 47.11 | 3.16 |
| EPS | 0.38 | ★ 4.57 |
| Revenue | ★ $16,507,289,161.00 | $6,948,000,000.00 |
| Revenue This Year | $78.18 | $8.00 |
| Revenue Next Year | $7.75 | $6.29 |
| P/E Ratio | ★ $8.45 | $31.93 |
| Revenue Growth | ★ 16.68 | 6.73 |
| 52 Week Low | $1.86 | $96.43 |
| 52 Week High | $3.77 | $160.27 |
| Indicator | BBD | A |
|---|---|---|
| Relative Strength Index (RSI) | 56.12 | 54.28 |
| Support Level | $3.36 | $143.14 |
| Resistance Level | $3.60 | $150.10 |
| Average True Range (ATR) | 0.07 | 3.20 |
| MACD | 0.01 | 0.80 |
| Stochastic Oscillator | 72.58 | 67.79 |
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.